Evommune (EVMN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
21 Apr, 2026Executive summary
Annual Meeting of Stockholders scheduled for June 2, 2026, to be held virtually.
Shareholders are invited to vote on key proposals, including director elections and auditor ratification.
Voting matters and shareholder proposals
Election of two Class I director nominees, Luis Peña and Eugene A. Bauer, to serve until the 2029 Annual Meeting.
Ratification of BDO USA, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026.
Proxies may vote on other business that arises during the meeting or any adjournments.
Board of directors and corporate governance
Board recommends voting in favor of both director nominees and the auditor ratification.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Evommune
- Advancing IL-18 and MRGPRX2 programs with strong funding and AI-driven innovation.EVMN
Morgan Stanley 24th Annual Global Healthcare Conference - Innovative therapies for inflammation, migraine, and autoimmunity advance toward late-stage trials.EVMN
Corporate presentation - Advancing two novel anti-inflammatory therapies with strong clinical and financial momentum.EVMN
Corporate presentation - Net loss rose to $53.9 million as expenses increased, but cash runway extends through 2028.EVMN
Q2 2026 - Directors and auditor were approved, with no shareholder questions and quorum established.EVMN
AGM 2026 - Advancing novel oral and biologic therapies for inflammation with strong clinical and financial momentum.EVMN
Corporate presentation - Net loss widened to $21.7 million in Q1 2026, with cash runway extended through 2028.EVMN
Q1 2026 - Shareholders will vote on director elections and auditor ratification, with strong governance and ESG oversight.EVMN
Proxy filing - Biotech enables resale of 4.5M shares post-IPO, advancing inflammation therapies amid sector risks.EVMN
Registration filing